Drug
Argx 113 With Rhuph20
Argx 113 With Rhuph20: highest development phase Phase 1, developed by Argenx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARGX-113 with rHuPH20 NCT04073589 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Argx 113 With Rhuph20 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.